Browse studies

Find your next paid study

26,899 recruiting studies available now

A Randomized, Controlled Trial to Examine the Effects of an Online Weight Loss Program Emphasizing Protein, Dietary Fiber, and Exercise (30-30-30 Plan) on Body Weight, Body Composition, and Other Cardiometabolic Risk Factors

The purpose of this study is to learn whether following an online weight loss program with specific dietary and exercise goals (the 30-30-30 plan) can help imp…

Overweight , Obesity

Estimated

~$10 – $7,500

Midwest Center for Metabolic and Cardiovascular ResearchNCT07789769

Phase 3

A Phase III Randomised, Parallel-Group, Double-Blind, Placebo-Controlled, Two-Arm Study to Evaluate the Efficacy and Safety of Elafibranor 80 mg on Long-Term Clinical Outcomes in Adult Participants With Primary Biliary Cholangitis (PBC)

The participants of this study will have confirmed Primary Biliary Cholangitis (PBC) and cirrhosis (scarring of the liver). PBC is a slowly progressive diseas…

Primary Biliary Cholangitis (PBC)

A Comparative Clinical Effectiveness Trial of Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab and Eculizumab To Prevent Relapses in Neuromyelitis Optica Spectrum Disorder

Neuromyelitis Optica Spectrum Disorder (NMOSD) is a rare autoimmune condition that mainly affects the eyes and spinal cord, causing serious symptoms such as vi…

NMOSD

Estimated

~$10 – $6,250

Massachusetts General HospitalNCT07010302

Phase 2

A Randomized, Open-label Study Evaluating the Efficacy and Safety of Cemacabtagene Ansegedleucel in Participants With Minimal Residual Disease After Response to First Line Therapy for Large B-cell Lymphoma

This is a randomized, open-label study in adult patients who have completed standard first line therapy for large B-cell lymphoma (LBCL) and achieved a complet…

Large B-cell Lymphoma

Estimated

~$10 – $8,750

Allogene TherapeuticsNCT06500273

Precision Prevention: Environmental Exposure Assessment in High-Risk and Early-Onset Breast Cancer Care

This study evaluates patient and provider attitudes about environmental exposure risk assessments into clinical care for female patients at average or high ris…

Breast Carcinoma

Estimated

~$10 – $750

City of Hope Medical CenterNCT07690852

Phase 1

Clinical Trial to Evaluate Short-term Safety of Subconjunctival Adalimumab in Combination With Type 1 Boston Keratoprosthesis Implantation

This trial is studying the safety and tolerability of receiving an injection of adalimumab (Humira) during the Boston Keratoprosthesis (KPro) surgery.

Penetrating KeratoplastyMultiple Graft FailureOcular Cicatricial Pemphigoid+1 more

Estimated

~$10 – $7,500

Massachusetts Eye and Ear InfirmaryNCT06926478

Phase 2

A Phase 2 Study of Elranatamab as Consolidation After Idecabtagene Vicleucel in Relapsed Refractory Multiple Myeloma

This research is being done to see if the study drug, elranatamab, reduces the risk of disease progression (worsening disease) after idecabtagene vicleucel in …

Refractory Multiple MyelomaRelapse Multiple MyelomaMultiple Myeloma

Estimated

~$10 – $6,250

Massachusetts General HospitalNCT06138275

Observational

Prospective Evaluation of New Techniques in Radiation Reduction for Cardiovascular Computed Tomographic Angiography

Title: Evaluating New Radiation Techniques for Cardiovascular Imaging Background: Cardiac CT angiography is associated with radiation exposure. Different met…

Coronary Disease

Estimated

~$10 – $5,625

National Heart, Lung, and Blood Institute (NHLBI)NCT01621594

Preserved vs. Reduced Ejection Fraction Biomarker Registry and Precision Medicine Database for Ambulatory Heart Failure Patients (PREFER-HF) Study

In this single-center, longitudinal observational study, we will comprehensively examine clinical characteristics, proteomic, metabolomic, genomic and imaging …

Heart Failure With Normal Ejection FractionHeart Failure With Reduced Ejection FractionHeart Failure, Right Sided+2 more

Estimated

~$10 – $750

Massachusetts General HospitalNCT03480633

Phase 2

A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of ORKA-002 in Adult Participants With Moderate-to-Severe Hidradenitis Suppurativa

This is a multicenter, randomized, double-blinded, placebo-controlled clinical study of ORKA-002 in adult participants with moderate-to-severe HS.

Hidradenitis Suppurativa (HS)

Estimated

~$10 – $8,750

Oruka Therapeutics, Inc.NCT07783542

Study of the Natural History, Pathogenesis and Outcome of Melorheostosis - a Rare Osteosclerotic Disease

Background: \- The rare disease melorheostosis causes bones to thicken. This may lead to pain, and can affect bones, joints, and muscles. Researchers want to …

Rheumatic Disease

Estimated

~$10 – $675

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)NCT02504879

Personalized Environment and Genes Study

Despite the overwhelming focus on genetic and genomic causes of human disease over the past two decades, it has been estimated that genetics is currently known…

DiabetesHeart DiseaseAsthma

Estimated

~$10 – $675

National Institute of Environmental Health Sciences (NIEHS)NCT00341237